These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 32423467)

  • 1. The design and statistical aspects of VIETNARMS: a strategic post-licensing trial of multiple oral direct-acting antiviral hepatitis C treatment strategies in Vietnam.
    McCabe L; White IR; Chau NVV; Barnes E; Pett SL; Cooke GS; Walker AS;
    Trials; 2020 May; 21(1):413. PubMed ID: 32423467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized comparison of daclatasvir + asunaprevir versus telaprevir + peginterferon/ribavirin in Japanese hepatitis C virus patients.
    Kumada H; Suzuki F; Suzuki Y; Toyota J; Karino Y; Chayama K; Kawakami Y; Fujiyama S; Ito T; Itoh Y; Tamura E; Ueki T; Ishikawa H; Hu W; McPhee F; Linaberry M; Hughes E
    J Gastroenterol Hepatol; 2016 Jan; 31(1):14-22. PubMed ID: 26252875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-rod and ring antibodies in patients with chronic hepatitis C using direct-acting antivirals.
    da Silva Sacerdote AB; Filgueira NA; de Barros Barreto S; Batista AD; Lopes EP
    Immunol Res; 2020 Jun; 68(3):111-117. PubMed ID: 32537670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High Efficacy and Safety of Flat-Dose Ribavirin Plus Sofosbuvir/Daclatasvir in Genotype 3 Cirrhotic Patients.
    Pellicelli A; Messina V; Giannelli V; Distefano M; Palitti VP; Vignally P; Tarquini P; Izzi A; Moretti A; Babudieri S; Dell'Isola S; Marignani M; Scifo G; Iovinella V; Cariti G; Pompili M; Candilo FD; Fontanella L; Ettorre GM; Vennarecci G; Ippolito AM; Barbarini G
    Gut Liver; 2020 May; 14(3):357-367. PubMed ID: 30970444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness and safety of sofosbuvir/velpatasvir ± ribavirin vs glecaprevir/pibrentasvir in genotype 3 hepatitis C virus infected patients.
    Margusino-Framiñán L; Cid-Silva P; Rotea-Salvo S; Mena-de-Cea Á; Suárez-López F; Vázquez-Rodríguez P; Delgado-Blanco M; Sanclaudio-Luhia AI; Martín-Herranz I; Castro-Iglesias Á
    Eur J Hosp Pharm; 2020 Mar; 27(e1):e41-e47. PubMed ID: 32296504
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient-reported outcomes with sofosbuvir and velpatasvir with or without ribavirin for hepatitis C virus-related decompensated cirrhosis: an exploratory analysis from the randomised, open-label ASTRAL-4 phase 3 trial.
    Younossi ZM; Stepanova M; Charlton M; Curry MP; O'Leary JG; Brown RS; Hunt S
    Lancet Gastroenterol Hepatol; 2016 Oct; 1(2):122-132. PubMed ID: 28404069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of chronic genotype-3 hepatitis C virus infection using direct-acting antiviral agents: An Indian experience.
    Goel A; Bhargava R; Rai P; Aggarwal R
    Indian J Gastroenterol; 2017 May; 36(3):227-234. PubMed ID: 28656492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A double-blind, randomized, placebo-controlled study to assess the safety, antiviral activity and pharmacokinetics of GSK2336805 when given as monotherapy and in combination with peginterferon alfa-2a and ribavirin in hepatitis C virus genotype 1-infected treatment-naive subjects.
    Gardner S; Cutrell A; Elko-Simms C; Adkison K; Hamatake R; Walker J; Rodriguez-Torres M; Hong Z
    Liver Int; 2014 Jul; 34(6):e89-95. PubMed ID: 24107072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sofosbuvir, ribavirin and pegylated interferon for a daclatasvir-resistent genotype 3 hepatitis C virus: case report and review.
    Mucenic M; Brandão ABM; Marroni CA; Fleck Junior AM; Zanotelli ML; Leipnitz I; Meine MH; Kiss G; Martini J; Schlindwein ES; Costabeber AM; Sacco FKR; Rossato G; Cantisani GPC
    Rev Inst Med Trop Sao Paulo; 2019 Feb; 61():e12. PubMed ID: 30785566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual treatment with sofosbuvir plus ribavirin is as effective as triple therapy with pegylated interferon plus sofosbuvir plus ribavirin in predominant genotype 3 patients with chronic hepatitis C.
    Satsangi S; Mehta M; Duseja A; Taneja S; Dhiman RK; Chawla Y
    J Gastroenterol Hepatol; 2017 Apr; 32(4):859-863. PubMed ID: 27624314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial.
    Kowdley KV; Lawitz E; Crespo I; Hassanein T; Davis MN; DeMicco M; Bernstein DE; Afdhal N; Vierling JM; Gordon SC; Anderson JK; Hyland RH; Dvory-Sobol H; An D; Hindes RG; Albanis E; Symonds WT; Berrey MM; Nelson DR; Jacobson IM
    Lancet; 2013 Jun; 381(9883):2100-7. PubMed ID: 23499440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of daclatasvir in hepatitis C virus.
    Izumi N
    Expert Rev Anti Infect Ther; 2014 Sep; 12(9):1025-31. PubMed ID: 25059552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single-centre, randomized controlled trial.
    Abbaspour Kasgari H; Moradi S; Shabani AM; Babamahmoodi F; Davoudi Badabi AR; Davoudi L; Alikhani A; Hedayatizadeh Omran A; Saeedi M; Merat S; Wentzel H; Garratt A; Levi J; Simmons B; Hill A; Tirgar Fakheri H
    J Antimicrob Chemother; 2020 Nov; 75(11):3373-3378. PubMed ID: 32812025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HCV direct-acting antiviral agents: the best interferon-free combinations.
    Schinazi R; Halfon P; Marcellin P; Asselah T
    Liver Int; 2014 Feb; 34 Suppl 1(Suppl 1):69-78. PubMed ID: 24373081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Results of sofosbuvir-based combination therapy for chronic hepatitis C cohort of Indian patients in real-life clinical practice.
    Sood A; Midha V; Mahajan R; Narang V; Mehta V; Wander P; Sharma S; Kaur K; Singh D
    J Gastroenterol Hepatol; 2017 Apr; 32(4):894-900. PubMed ID: 27787910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of Sofosbuvir Plus Ribavirin with or Without Peginterferon- Alfa in Treatment of a Cohort of Egyptian Patients with Hepatitis C Virus Infection.
    Ahmed OA; Kaisar HH; Hawash N; Samir H; Shabana SST; Hassan A Fouad M; Rizk F; Abd-Elsalam S
    Infect Disord Drug Targets; 2017; 17(2):95-100. PubMed ID: 28413993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combinations of two drugs among NS3/4A inhibitors, NS5B inhibitors and non-selective antiviral agents are effective for hepatitis C virus with NS5A-P32 deletion in humanized-liver mice.
    Doi A; Hikita H; Kai Y; Tahata Y; Saito Y; Nakabori T; Yamada R; Kodama T; Sakamori R; Murayama A; Nitta S; Asahina Y; Suemizu H; Tatsumi T; Kato T; Takehara T
    J Gastroenterol; 2019 May; 54(5):449-458. PubMed ID: 30684016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sofosbuvir plus ribavirin with or without peginterferon for the treatment of hepatitis C virus: Results from a phase 3b study in China.
    Wei L; Xie Q; Hou JL; Jia J; Li W; Xu M; Li J; Wu S; Cheng J; Jiang J; Wang G; Yang Y; Mou Z; Gao ZL; Gong G; Niu JQ; Hu P; Tang H; Lin F; Dou X; Li L; Zhang LL; Nan Y; Massetto B; Yang JC; Knox SJ; Kersey K; German P; Mo H; Jiang D; Brainard DM; Jiang J; Ning Q; Duan Z
    J Gastroenterol Hepatol; 2018 Jun; 33(6):1168-1176. PubMed ID: 29380415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative efficacy of sofosbuvir-ribavirin versus sofosbuvir-daclatasvir for treatment of chronic hepatitis C in an area with limited NS5A inhibitor availability.
    Kurniawan J; Gani RA; Hasan I; Sulaiman AS; Lesmana CRA; Jasirwan COM; Kalista KF; Nababan SHH; Zulkifly S
    Indian J Gastroenterol; 2018 Nov; 37(6):520-525. PubMed ID: 30637537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of sofosbuvir-velpatasvir with or without ribavirin in HCV-infected Japanese patients with decompensated cirrhosis: an open-label phase 3 trial.
    Takehara T; Sakamoto N; Nishiguchi S; Ikeda F; Tatsumi T; Ueno Y; Yatsuhashi H; Takikawa Y; Kanda T; Sakamoto M; Tamori A; Mita E; Chayama K; Zhang G; De-Oertel S; Dvory-Sobol H; Matsuda T; Stamm LM; Brainard DM; Tanaka Y; Kurosaki M
    J Gastroenterol; 2019 Jan; 54(1):87-95. PubMed ID: 30203225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.